Form D · Biotechnology
Koligo Therapeutics, Inc.
New Albany, IN · CIK 0001707597
Offering snapshot reported Oct 7, 2020 · SEC filing
- Reported sold
- $1.65M Offering amount: $1.65M
- Investors reported
- 2 Form D · investor count
- Minimum accepted
- $20K Reported outside-investor minimum
- First sale
- Sep 25, 2020 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Oct 7, 2020 | Initial | $1,646,759 | No comparison | 2 | SEC filing |
| Mar 7, 2018 | Initial | $2,000,000 | No comparison | 1 | SEC filing |
| Dec 14, 2017 | Initial | $5,000 | No comparison | 6 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-377285
Source: Form D, filed Oct 7, 2020. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Balamurugan Appakalai | Director, Executive |
| David Blanford | Director, Executive |
| Michael Hughes | Director, Executive |
| Matthew Lehman | Executive |
| Stuart Williams | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
2113 State Street
New Albany, IN, 47150
New Albany, IN, 47150